Skip to main content

Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · Delayed Price · USD
23.10 -0.82 (-3.43%)
Sep 24, 2021 3:23 PM EDT - Market open
Market Cap1.20B
Revenue (ttm)n/a
Net Income (ttm)-150.30M
Shares Out50.24M
EPS (ttm)-3.38
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume138,786
Open23.68
Previous Close23.92
Day's Range22.88 - 24.13
52-Week Range17.51 - 38.49
Betan/a
AnalystsStrong Buy
Price Target54.88 (+137.6%)
Est. Earnings DateNov 4, 2021

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ...

IndustryBiotechnology
IPO DateJan 31, 2020
Employees108
Stock ExchangeNASDAQ
Ticker SymbolARQT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price forecast is 54.88, which is an increase of 137.58% from the latest price.

Price Target
$54.88
(137.58% upside)
Analyst Consensus: Strong Buy

News

Is Now the Time to Bet on Arcutis Biotherapeutics?

Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

6 days ago - The Motley Fool

Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-...

2 weeks ago - GlobeNewsWire

Arcutis Announces Appointment of Keith Leonard to Board of Directors

WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address...

3 weeks ago - GlobeNewsWire

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

1 month ago - GlobeNewsWire

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

1 month ago - GlobeNewsWire

Arcutis Announces Additions to its Investor Relations and Communications Team

WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address ...

1 month ago - GlobeNewsWire

All You Need to Know About Arcutis Biotherapeutics, Inc. (ARQT) Rating Upgrade to Buy

Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psori...

WESTLAKE VILLAGE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- In order to address a major limitation of today's most widely used method for gauging severity of plaque psoriasis (the PASI scale), Arcutis B...

2 months ago - GlobeNewsWire

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potenti...

WESTLAKE VILLAGE, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

2 months ago - GlobeNewsWire

Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

2 months ago - Zacks Investment Research

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo.  The study was initiated in March 2021.

2 months ago - Benzinga

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

WESTLAKE VILLAGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), today announced its decision to terminate the recently initiated Phase 2a clinical trial evalua...

2 months ago - GlobeNewsWire

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

3 months ago - GlobeNewsWire

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

3 months ago - GlobeNewsWire

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

WESTLAKE VILLAGE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

3 months ago - GlobeNewsWire

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for u...

4 months ago - GlobeNewsWire

Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) S...

Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical once-daily treatment for chronic...

4 months ago - GlobeNewsWire

Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body psoriasis. Data were presented in a late-breaking or...

5 months ago - Benzinga

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of ...

WESTLAKE VILLAGE, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

5 months ago - GlobeNewsWire

Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting ...

Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-dai...

5 months ago - GlobeNewsWire

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic D...

WESTLAKE VILLAGE, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

5 months ago - GlobeNewsWire

Arcutis Announces Updates to its Executive Team

WESTLAKE VILLAGE, Calif., March 26, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

5 months ago - GlobeNewsWire

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for V...

WESTLAKE VILLAGE, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

6 months ago - GlobeNewsWire

Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream fo...

Poster presentations highlight new data for roflumilast cream, including long-term safety and efficacy results in adults with chronic plaque psoriasis Poster presentations highlight new data for roflumi...

6 months ago - GlobeNewsWire

Arcutis to Present at the Cowen 41st Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

6 months ago - GlobeNewsWire